Tectonic Therapeutic (TECX) Stock Price, News & Analysis

Company Overview

Tectonic Therapeutic, Inc. (NASDAQ: TECX) is a clinical-stage biotechnology company developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in numerous biological processes and are established targets for a range of therapeutic treatments, but many remain difficult to address with conventional drug-discovery approaches.

The company uses its proprietary GEODe platform to identify and develop antibodies and other biologic molecules designed to modulate GPCR activity. Its research and development efforts are focused on creating therapies for serious diseases in areas where current treatment options may be limited.

Tectonic’s lead program, TX45, is an engineered relaxin-based therapeutic intended to activate the RXFP1 receptor. The program has been investigated for potential treatment of pulmonary arterial hypertension and other cardiovascular conditions. Tectonic Therapeutic is based in the United States and focuses primarily on advancing its internal discovery and clinical development pipeline.

Key Stats

• Today's Range: $22.74 to $23.61
• 50-Day Range: $22.41 to $37.71
• 52-Week Range: $15.45 to $39.53
• Volume: 110,701 shs
• Average Volume: 263,435 shs
• Market Capitalization: $456.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $77.80
• Consensus Rating: Moderate Buy

Tectonic Therapeutic Stock Analysis - MarketRank™

Tectonic Therapeutic scored higher than 53% of companies evaluated by MarketBeat, and ranked 513th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tectonic Therapeutic has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tectonic Therapeutic has a consensus price target of $77.80, representing about 231.7% upside from its current price of $23.45.

Amount of Analyst Coverage

Tectonic Therapeutic has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tectonic Therapeutic are expected to decrease in the coming year, from ($5.27) to ($5.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tectonic Therapeutic is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tectonic Therapeutic is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tectonic Therapeutic has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.85% of the float of Tectonic Therapeutic has been sold short.

Short Interest Ratio / Days to Cover

Tectonic Therapeutic has a short interest ratio ("days to cover") of 13.01, which indicates bearish sentiment.

Change versus previous month

Short interest in Tectonic Therapeutic has recently increased by 14.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tectonic Therapeutic does not currently pay a dividend.

Dividend Growth

Tectonic Therapeutic does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.53

News Sentiment

Tectonic Therapeutic has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Tectonic Therapeutic this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tectonic Therapeutic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,425.00 in company stock.

Percentage Held by Insiders

39.80% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TECX
• Previous Symbol: NASDAQ:TECX
• CIK: 1681087
• Web: www.tectonictx.com
• Phone: 617-914-8420
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tectonic Therapeutic: $77.80
• High Price Target: $93.00
• Low Price Target: $60.00
• Potential Upside/Downside: +233.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.26%
• Return on Assets: -33.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.29
• Quick Ratio: 22.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.43 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 19,549,000
• Free Float: 11,768,000
• Market Cap: $456.08 million
• Optionable: N/A
• Beta: 3.28